Jacob Fund released its third-quarter 2025 investor letter, showing continued market recovery with major equity indexes reaching all-time highs. Finalized tariffs had limited economic impact, stabilizing the market. The fund anticipates a new productivity cycle enhancing profit margins and earnings growth, focusing on companies poised for growth and improved valuation multiples.

Inogen, Inc. (NASDAQ:INGN) was highlighted in the investor letter, a medical device company with a one-month return of -1.14%. Shares lost 27.02% over the last 52 weeks, closing at $6.94 per share on December 05, 2025, with a market cap of $188.41 million. The fund added Inogen, Omeros, and Bed Bath & Beyond to its portfolio.

In its investor letter, Jacob Fund praised Inogen, Inc. (NASDAQ:INGN) for its portable oxygen concentrators for patients with chronic respiratory conditions. Despite past struggles, the company has stabilized, leading in market share and brand recognition. New management has improved profitability and innovation, anticipating continued growth due to the aging population.

Inogen, Inc. (NASDAQ:INGN) is not among the 30 Most Popular Stocks Among Hedge Funds, with 21 hedge fund portfolios holding it at the end of the third quarter. While acknowledging its potential, some AI stocks offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks can explore opportunities in the market.

Read more at Yahoo Finance: Here’s What Will Fuel Inogen’s (INGN) Future Growth